Five Prime Therapeutics CEO Aron Knickerbocker's 2018 pay falls 71% to $2.1M
Five Prime Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 29, 2019
Five Prime Therapeutics reported fiscal year 2018 executive compensation information on April 29, 2019.
In 2018, seven executives at Five Prime Therapeutics received on average a compensation package of $1.3M, a 67% decrease compared to previous year.
Average pay of disclosed executives at Five Prime Therapeutics
Aron M. Knickerbocker, Chief Executive Officer, received $2.1M in total, which decreased by 71% compared to 2017. 51% of Knickerbocker's compensation, or $1.1M, was in option awards. Knickerbocker also received $225K in non-equity incentive plan, $500K in salary, $280K in stock awards, as well as $6.1K in other compensation.
For fiscal year 2018, the median employee pay was $201,670 at Five Prime Therapeutics. Therefore, the ratio of Aron M. Knickerbocker's pay to the median employee pay was 10 to one.
David V. Smith, Chief Financial Officer, received a compensation package of $2M. 73% of the compensation package, or $1.5M, was in option awards.
Bryan Irving, Chief Scientific Officer, earned $1.4M in 2018.
Helen Collins, Chief Medical Officer, received $1.3M in 2018, which decreases by 51% compared to 2017.
Francis W. Sarena, Secretary, earned $1.3M in 2018, a 53% decrease compared to previous year.
Linda Rubinstein, Chief Financial Officer, received $530K in 2018.
Marc Belsky, Chief Financial Officer, earned $415K in 2018, a 78% decrease compared to previous year.
Related executives
Aron Knickerbocker
Five Prime Therapeutics
Chief Executive Officer
David Smith
Five Prime Therapeutics
Chief Financial Officer
Bryan Irving
Five Prime Therapeutics
Chief Scientific Officer
Helen Collins
Five Prime Therapeutics
Chief Medical Officer
Francis Sarena
Five Prime Therapeutics
Secretary
Marc Belsky
Five Prime Therapeutics
Chief Financial Officer
Linda Rubinstein
Five Prime Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on April 29, 2019.